JP7557377B2 - 三量体ポリペプチド複合体およびその使用 - Google Patents

三量体ポリペプチド複合体およびその使用 Download PDF

Info

Publication number
JP7557377B2
JP7557377B2 JP2020567523A JP2020567523A JP7557377B2 JP 7557377 B2 JP7557377 B2 JP 7557377B2 JP 2020567523 A JP2020567523 A JP 2020567523A JP 2020567523 A JP2020567523 A JP 2020567523A JP 7557377 B2 JP7557377 B2 JP 7557377B2
Authority
JP
Japan
Prior art keywords
cancer
cells
tumor
trimeric polypeptide
polypeptide complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020567523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525537A (ja
JPWO2019234187A5 (https=
JP2021525537A5 (https=
Inventor
グラウ、マルタ コンプテ
バジナ、ルイス アルバレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEADARTIS SL
Original Assignee
LEADARTIS SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEADARTIS SL filed Critical LEADARTIS SL
Publication of JP2021525537A publication Critical patent/JP2021525537A/ja
Publication of JPWO2019234187A5 publication Critical patent/JPWO2019234187A5/ja
Publication of JP2021525537A5 publication Critical patent/JP2021525537A5/ja
Application granted granted Critical
Publication of JP7557377B2 publication Critical patent/JP7557377B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020567523A 2018-06-06 2019-06-06 三量体ポリペプチド複合体およびその使用 Active JP7557377B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382401.0 2018-06-06
EP18382401 2018-06-06
PCT/EP2019/064864 WO2019234187A1 (en) 2018-06-06 2019-06-06 Trimeric polypeptide complexes and uses thereof

Publications (4)

Publication Number Publication Date
JP2021525537A JP2021525537A (ja) 2021-09-27
JPWO2019234187A5 JPWO2019234187A5 (https=) 2022-06-14
JP2021525537A5 JP2021525537A5 (https=) 2022-06-14
JP7557377B2 true JP7557377B2 (ja) 2024-09-27

Family

ID=62716010

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567523A Active JP7557377B2 (ja) 2018-06-06 2019-06-06 三量体ポリペプチド複合体およびその使用

Country Status (5)

Country Link
US (1) US12454577B2 (https=)
EP (1) EP3802601A1 (https=)
JP (1) JP7557377B2 (https=)
CN (1) CN112566939A (https=)
WO (1) WO2019234187A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021285201A1 (en) * 2020-06-05 2022-11-24 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1BB
WO2021249010A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus diagnostic compositions, methods, and uses thereof
US20230303664A1 (en) * 2020-07-29 2023-09-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic and diagnostic vhh antibodies against sars-cov-2 and methods for their enhancement
EP3944877A1 (en) * 2020-07-29 2022-02-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nanobodies sars-cov2
EP3957650A1 (en) 2020-08-17 2022-02-23 Themis Bioscience GmbH Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation
WO2022184937A1 (en) * 2021-03-05 2022-09-09 Leadartis, S.L. Trimeric polypeptides and uses thereof in the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012049328A1 (en) 2010-10-15 2012-04-19 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain
WO2015156268A1 (ja) 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子
WO2017098005A1 (en) 2015-12-11 2017-06-15 Leadartis, S.L. Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
CA2155335C (en) 1993-02-04 2001-06-05 HANS CHRISTIAN THõGERSEN Improved method for the refolding of proteins
AU2017252233A1 (en) 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012049328A1 (en) 2010-10-15 2012-04-19 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain
WO2015156268A1 (ja) 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子
WO2017098005A1 (en) 2015-12-11 2017-06-15 Leadartis, S.L. Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. J. Hinner, et al.，Journal for ImmunoTherapy of Cancer，2015年，Vol.3 (Suppl 2)，P187
S. L. Harwood, et al.，ONCOIMMUNOLOGY，2018年，Vol.7, No.1:e1377874，p.1-14, Supplementary Information:p.1-7

Also Published As

Publication number Publication date
CN112566939A (zh) 2021-03-26
WO2019234187A1 (en) 2019-12-12
JP2021525537A (ja) 2021-09-27
US20210246217A1 (en) 2021-08-12
EP3802601A1 (en) 2021-04-14
US12454577B2 (en) 2025-10-28

Similar Documents

Publication Publication Date Title
JP7557377B2 (ja) 三量体ポリペプチド複合体およびその使用
US11780919B2 (en) Bispecific antigen binding molecules targeting OX40 and FAP
TWI713474B (zh) 包含ｔｎｆ家族配位三聚體之抗原結合分子
EP3733715A1 (en) Triabody, preparation method and use thereof
CN114245806A (zh) EpCAM结合蛋白及使用方法
US20190016771A1 (en) Trimeric costimulatory tnf family ligand-containing antigen binding molecules
KR20220121850A (ko) 항-cd73 항체 및 이의 용도
TW202005984A (zh) 結合pd-l1及cd137的抗體分子
KR20240073008A (ko) Cd137 및 종양 연관 항원에 결합하는 이중특이적 결합 단백질
US12428493B2 (en) Antibodies that bind PSMA and gamma-delta T cell receptors
KR20160142332A (ko) 면역활성화 항원 결합 분자
TWI903448B (zh) 對抗檢查點分子之多特異性結合構築體及其用途
CN113727731B (zh) 靶向pd-1和lag-3的双特异性抗体
US20240092942A1 (en) Trimeric polypeptides and uses thereof in the treatment of cancer
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途
HK40118852A (zh) 对抗检查点分子的多特异性结合构建体及其用途
EA048596B1 (ru) Антитела, которые связывают psma и гамма-дельта рецепторы т-клеток
HK40108926A (zh) 三聚体多肽及其在治疗癌症中的用途
TW202604964A (zh) 對抗檢查點分子之多特異性結合構築體及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240913

R150 Certificate of patent or registration of utility model

Ref document number: 7557377

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150